Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - Semperit, Valneva (01/07/2024)

07.07.2024

Semperit: Semperit has completed the sale of the medical business and transferred the remaining production and packaging of surgical gloves to the buyer of the entire medical business, the Southeast Asian Harps Global, as agreed. The second and final closing of the sale of the medical business took place with effect from June 30, 2024, and comprised the sale of the operation for the contract manufacturing of surgical gloves in Wimpassing, Austria, and the 100% stake in the Hungarian company Sempermed Kft., which carries out their packaging in Sopron, Hungary. The sales price (cash and debt free) amounts to EUR 7 million.
Semperit: weekly performance: -1.84%

Valenva: Valneva, an Austrian/French specialty vaccine company, announced that the European Commission (EC) has granted marketing authorization in Europe for Valneva’s single-dose vaccine, IXCHIQ®, for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older. The EC decision marks the third approval the Company has received for IXCHIQ® following approval from the U.S. Food and Drug Administration (FDA) in November 2023 and Health Canada last month. The Company expects to deliver the first doses in Europe in the fourth quarter of 2024. IXCHIQ® is the world’s only licensed chikungunya vaccine available to address this unmet medical need. In accordance with the International Recognition Procedure (IRP)[, Valneva has also submitted a Marketing Authorization Application (MAA) to the UK Medicines and Healthcare products Regulatory Agency (MHRA). An additional marketing authorization application is under review by the Brazilian Health Regulatory Agency (ANVISA) to make the vaccine available in certain Low- and Middle-Income Countries (LMIC), with potential approval in 2024.
Valneva: weekly performance: 0.57%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (01/07/2024)


Partners









latest 21st Austria

21st Austria weekly - Semperit, Valneva (01/07/2024)


07.07.2024, 1913 Zeichen



Semperit: Semperit has completed the sale of the medical business and transferred the remaining production and packaging of surgical gloves to the buyer of the entire medical business, the Southeast Asian Harps Global, as agreed. The second and final closing of the sale of the medical business took place with effect from June 30, 2024, and comprised the sale of the operation for the contract manufacturing of surgical gloves in Wimpassing, Austria, and the 100% stake in the Hungarian company Sempermed Kft., which carries out their packaging in Sopron, Hungary. The sales price (cash and debt free) amounts to EUR 7 million.
Semperit: weekly performance: -1.84%

Valenva: Valneva, an Austrian/French specialty vaccine company, announced that the European Commission (EC) has granted marketing authorization in Europe for Valneva’s single-dose vaccine, IXCHIQ®, for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older. The EC decision marks the third approval the Company has received for IXCHIQ® following approval from the U.S. Food and Drug Administration (FDA) in November 2023 and Health Canada last month. The Company expects to deliver the first doses in Europe in the fourth quarter of 2024. IXCHIQ® is the world’s only licensed chikungunya vaccine available to address this unmet medical need. In accordance with the International Recognition Procedure (IRP)[, Valneva has also submitted a Marketing Authorization Application (MAA) to the UK Medicines and Healthcare products Regulatory Agency (MHRA). An additional marketing authorization application is under review by the Brazilian Health Regulatory Agency (ANVISA) to make the vaccine available in certain Low- and Middle-Income Countries (LMIC), with potential approval in 2024.
Valneva: weekly performance: 0.57%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (01/07/2024)



BSN Podcasts
Christian Drastil: Wiener Börse Plausch

Börsenradio Live-Blick, Do. 21.11.24: DAX unter 19.000, Big Short bei Siemens Energy, Symrise optimistischer, Gold steigt stark




 

Bildnachweis

Aktien auf dem Radar:Pierer Mobility, DO&CO, Semperit, Addiko Bank, Immofinanz, CA Immo, Rosgix, Zumtobel, Linz Textil Holding, AT&S, Wienerberger, FACC, EuroTeleSites AG, EVN, Österreichische Post, Gurktaler AG VZ, Kostad, Kapsch TrafficCom, Josef Manner & Comp. AG, Polytec Group, Warimpex, Porr, Oberbank AG Stamm, Palfinger, Agrana, Amag, Flughafen Wien, OMV, S Immo, Telekom Austria, Uniqa.


Random Partner

AMAG Austria Metall AG
Die AMAG Austria Metall AG produziert Primäraluminium und Premium-Guss- und Walzprodukte. Im integrierten Werk in Ranshofen, Österreich werden die Kernkompetenzen im Recycling, Gießen, Walzen, Wärmebehandeln und Oberflächenveredeln kombiniert.

>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten